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Abstract
Fanconi anemia (FA), an inherited disease, is associated with progressive bone marrow failure, predisposition to cancer, and
genomic instability. Genes corresponding to 15 identified FA complementation groups have been cloned, and each gene
product functions in the response to DNA damage induced by cross-linking agents and/or in protection against genome
instability. Interestingly, overproduction of inflammatory cytokines such as tumor necrosis factor alpha (TNF-a) and aberrant
activation of NF-kB-dependent transcriptional activity have been observed in FA cells. Here we demonstrated that FANCD2
protein inhibits NF-kB activity in its monoubiquitination-dependent manner. Furthermore, we detected a specific association
between FANCD2 and an NF-kB consensus element in the TNF-a promoter by electrophoreticmobility shift assays (EMSA) and
chromatin immunoprecipitation (ChIP) assay. Therefore, we propose FANCD2 deficiency promotes transcriptional activity of
the TNF-a promoter and induces overproduction of TNF-which thensustains prolonged inflammatory responses.Theseresults
also suggest that artificial modulation of TNFa production could be a promising therapeutic approach to FA.
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Introduction
Fanconi anemia (FA) is a genetic disorder associated with genome
instability and mainly characterized by progressive bone marrow
failure, congenital abnormalities, and predisposition to cancer[1,2].
T od a t e ,1 5F Ag e n ep r o d u c t s( F A N C A ,B ,C ,D 1 ,D 2 ,E ,F ,G ,I ,J ,L ,
M, N, O and P) have been identified and they constitute the FANC
pathway, which is thought to function in preventing genome
instability[1,2,3,4]. The FA core complex comprises FAAP24,
F A A P 1 0 0 ,a n d8F Ap r o t e i n s( F A N C A ,B ,C ,E ,F ,G ,L ,a n dM )
and mediates DNA-damage-induced or replication-stress-induced
monoubiquitylation of FANCD2 and FANCI[1]. Monoubiquitinated
FANCD2 and FANCI translocate to chromatin and function in DNA
repair at least partially by recruitment of FAN1 nuclease[5,6,7].
Defective self-renewal of hematopoietic stem cells causes bone
marrow failure, and its consequences (e.g. pancytopenia or myeloid
malignancies) are the major cause of morbidity in FA patients[7].
Two different mechanisms, which are not necessarily mutually
exclusive, may contribute to the development of the bone marrow
failure in FA. First, DNA repair function of the FANC pathway
seems necessary to maintain hematopoietic stem cell, and the
compromised DNA repair activity in FA patients results in the
accumulation of unrepaired DNA, leading to genome instability and
depletion of functional hematopoietic stem cells[1,8]. Second, it has
been suggested that hematopoietic disorders in FA patients may
result from hypersensitivity to cytokines, such as TNF-a;f o r
example, cells lacking FANCC, a core complex component, are
hypersensitiveto the apoptoticeffectof a pro-inflammation cytokine,
TNF-a[9,10,11,12,13,14]. Furthermore, abnormally elevated levels
of serum and intracellular TNF-a have been reported in FA patients
[15,16]. Consistent with this, in FANCC-deficient murine hemato-
poietic stem cells, TNF-aoverproduction results in bone marrow
hypoplasia, and long-term exposure of these cells to TNF-a induces
clonal evolution that leads to myelogenous leukemia[13,17]. The
possibility of clinical trial of anti-TNF-a agents for the treatment of
selected FA patients has been proposed [18]. However, definitive
evidence for functional crosstalk between other FA proteins, such as
FANCD2, and cytokine response/overproduction is lacking.
In this work, we identified that direct association of FANCD2
and NF-kB consensus sequence (kB1site) in TNF-apromoter,
leading to the repression of its transcriptional activity. Thus
FANCD2 deficiency triggered TNF-a overproduction, which is
reportedly a major cause of morbidity in FA mutant mice[17,19].
Results
FANCD2 deficiency enhances TNF-a-induced NF-kB-
dependent transcriptional activity
TNF-a triggers several signaling pathways that converge on the
activation of NF-kB, a transcription factor that is constitutively
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e23324activated in FA cells and FANCC knockdown cells activated by
TLR8 agonists[20,21,22]. We examined the role of FA proteins in
NF-kB-dependent transcriptional activity induced by TNF-a.W e
compared three type of cells—a patient-derived FANCD2 mutant
fibroblast cell line PD20 (FA-D2), PD20 cells complemented with
a retrovirus containing the functional human FANCD2 cDNA
(FA-D2/D2), and PD20 stably transduced with an empty vector
(FA-D2/vec). We also included a patient-derived FANCC-/-
fibroblast cell line PD331 (FA-C) and its derivative retrovirally
transduced with FANCC (FA-C/C). All of these cells were
transiently transfected with an NF-kB-dependent luciferase
reporter plasmid containing four copies of the NF-kB consensus
sequences (pNFkB-Luc). TNF-a-induced activation of NF-kB was
higher in FANCD2-deficient cells (FA-D2, FA-D2/vec) than in
FANCD2-proficient cells (FA-D2/D2); similarly, FANCC-defi-
cient cells (FA-C) had higher levels of TNF-a-induced NF-kB
activation than did the FANCC-proficient cells (FA-C/
FANCC)(Fig 1A) We also showed that transiently expression of
FANCD2WT repressed enhanced NF-kB transcriptional activity
of FANCD2-deficient cells (FA-D2/vec). However, mutant
FANCD2 (FANCD2K561R; a missense substitution at mono-
ubiquitination site (K561)) and FANCC did not repress (Figure
S1A). Moreover, there was not significant differences in TNF-a-
induced NF-kB activation between FANCA-deficient cells (FA-A)
and FANCA-proficient cells (FA-A/FANCA) (Fig. S1B).These
data suggested that NF-kB transcriptional activity was influenced
by FANCC and FANCD2. Several DNA-damaging agents that
induce DNA double-strand breaks (e.g., ionizing radiation (IR))
elicit NF-kB-dependent transcription by activating ataxia telangi-
ectasia-mutated kinase (ATM)[23]. MMC, a chemotherapeutic
drug that induces formation of intra- and inter-strand DNA
crosslinks, and UV also activate NF-kB[24,25]. Therefore, we
assessed the functional effect of FANCD2 on NF-kB following X-
ray, UV, or MMC treatment; the FANCD2 deficiency did not
affect the NF-kB-dependent transcriptional activity induced by
any of these DNA-damaging agents (Fig. 1B). These data
suggested that NF-kB transcriptional activity induced by mecha-
nisms other than TNF-a was not significantly enhanced in
FANCD2-deficient cells.
FANCD2-deficient fibroblast cells were more sensitive to
TNF-a
Pro-inflammatory cytokines inactivate the inhibitor protein
IkBa, which sequesters NF-kB proteins in the cytoplasm. The
multimeric IkB kinase (IKK) complex phosphorylates IkBa,
resulting in the ubiquitination and degradation of IkBa, which
in turn cause the release and nuclear translocation of NF-kB[26].
IkBa is an NF-kB target gene, and re-synthesis of IkBa terminates
NF-kB activity by its nuclear export[27]. To confirm that the
FANCD2 deficiency enhanced NF-kB activity, we quantified IkBa
phosphorylation and the subsequent IkBa degradation in
FANCD2-deficient and FANCD2-proficient cells. FANCD2-
deficient cells (FA-D2/vec) treated with or without TNF-a showed
significantly enhanced IkBa phosphorylation and decreased
amounts of IkBa relative to complemented FANCD2 cells (FA-
D2/D2) (Fig. 2A). We also examined the termination of TNF-a
induced NF-kB activity in FA cells, using IkBa levels as a marker.
The amount of IkBaprotein was represented as the ratio of IkBa
protein to a-tubulin and normalized with respect to unstimulated
FA-D2/vec cells. A 4-h exposure to TNF-ainduced transient loss
and subsequent resynthesis of IkBa protein in FANCD2-deficient
(FA-D2/vec) and FANCD2-proficient cells (FA-D2/D2) (Fig. 2B).
However, after 24-h TNF-a exposure, the amount of IkBa protein
was lower and the reduction was prolonged in FANCD2-deficient
cells relative to FANCD2-proficient cells (Fig. 2B). We also
observed that the TNF-a induced nuclear translocation of RelA/
p65, which is one of the dimeric NF-kB transcriptional complex,
was significantly higher in FANCD2-deficient cells than in control
cells (Fig. 3A, B). Collectively, these data suggested that FANCD2
has a negative regulatory function in TNF-a-induced NF-kB
activation.
Inhibition of NF-kB activity and expression of TNF-a
mRNA by FANCD2
TotesttheabilityofFANCD2andotherFAproteinstomodulate
NF-kB-dependent transcriptional activity, HEK293 cells were
transfected with an NF-kB-dependent luciferase reporter plasmid
(pNFkB-Luc) and FA protein cDNA. As expected, overexpression
of FANCD2 inhibited TNF-a-induced NF-kB-dependent tran-
scriptional activity. However, FANCG, FANCI and a mutant
FANCD2 (FANCD2K561R (K561)) did not inhibit NF-kB activity.
FANCC also did not significantly inhibit (p=0.09739). In addition,
we used a FANCD2 derivative FANCD2KR fused with a single
ubiquitin moiety (FANCD2K561R-Ub), which was previously
shown to restore near wild-type levels of cisplatin tolerance in
FANCD2-deficient cells[28]. We found that TNF-a-induced NF-
kB-dependent transcriptional activity was similar in FANCD2KR-
Ub-expressingand FANCD2-expressingcells(Fig.4A).Asapositive
control, we confirmed that knockdown of endogeneous p65 with a
pool of four distinct siRNA duplexes repressed TNF-ainduced NF-
kB activation compared with control scrambled siRNA (Fig.S2).
These data indicated that FANCD2 negatively regulated NF-kB
transcriptional activity in a monoubiquitination dependent manner.
Following TNF-a stimulation, TNF-a transcript levels were
significantly higher in FANCD2-deficient cells than in FANCD2-
proficient cells (Fig. 4B). Collectively, these data indicate that
FANCD2 suppresses NF-kB transcriptional activity, and that
FANCD2 deficiency enhanced expression of TNF-amRNA.
FANCD2 represses TNF-a promoter activity
To assess whether FANCD2 could directly inhibit the
expression of TNF-a, FANCD2-deficient cells were transfected
with FANCD2 or FANCD2KR cDNA, and relative TNF-a
mRNA levels were quantified. The elevated expression of TNF-
ainFANCD2-deficient cells was decreased when FANCD2, but
not FANCD2KR, was transiently expressed with or without TNF-
a (Fig. 5A). Next, we examined the regulation of TNF-a promoter
activity by FANCD2. FANCD2-deficient cells (FA-D2/vec) and
FANCD2-expressing cells (FA-D2/D2) were transfected with a
reporter plasmid (pTNF-˜ aluc expressing firefly luciferase under
the control of the human TNF-a promoter (Fig. 5B). Relative
TNF-a promoter activity was significantly higher in FANCD2-
deficient cells than in FANCD2-proficient cells (Fig. 5B). These
results suggested that FANCD2 directly inhibit TNF-a transcrip-
tion by repressing TNF-a promoter activity.
FANCD2 directly binds to NF-kB consensus in TNF-a
promoter
Because TNF-a plays an important role in diverse cellular
events such as induction of other cytokines, cell proliferation,
differentiation, and apoptosis[29], the regulation of TNF-a
expression is tightly controlled by several transcription factors,
including NF-kB[30], NF-AT[31], or activating protein I (AP-
1)[32]. For example, multiple NF-kB/Rel-binding sites in the
mouse TNF-a promoter contribute to the TNF-a transcriptional
response to lipopolysaccharide (LPS)[30], and these binding sites
are designated as kB1, kB2kB2and kB3. NF-kB-like sites (kB1,
Fanconi Anemia Protein FANCD2 Regulates TNF-a
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identified[33] Fig. 6A Of these NF-kB-like sites, kB1 apparently
has the highest affinity for NF-kB/Rel proteins[34]. To
investigate how FANCD2 suppresses TNF-a promoter activity,
we performed electrophoretic mobility shift assays (EMSA) with
the recombinant FANCD2 protein and oligonucleotides derived
Figure 1. Deficiency of FANCD2 increases TNF-a-induced NF-kB-dependent transcriptional activity. (A) FA fibroblast cells derived from
complementation group C and group D2 patients were designated FA-C (PD331) and FA-D2 (PD20), respectively. FA-C/C (FA-C; (PD331)+FANCC) and
FA-D2/ D2 (FA-D2; (PD20)+FANCD2) were retrovirus-transformed derivatives of PD331 and PD20 that expressed functional FANCC and FANCD2,
respectively. FA-D2/vec cells (FA-D2 expressing empty vector) were FANCD2-deficient derivatives of PD20. FA-D2 cells (FA-D2 and FA-D2/vec) showed
higher TNF-a-induced NF-kB-dependent transcriptional activity than did the FANCD2-expressing cells (FA-D2/D2); similarly FANCC-deficient cells (FA-
C) exhibited more NF-kB-dependent transcriptional activity than did FANCC-expressing cells (FA-C/C). FA fibroblasts were transfected with pNFkB-
Luc (100 ng) and pRL-CMV (10 ng). Cells were treated with or without TNF-a (20 ng/ml) for 8 h. Cells were harvested and dual luciferase assays were
performed. Fold activation represents the mean (6 s.d) luciferase values of indicated cells normalized with respect to unstimulated FA-D2 cells, from
three independent experiments. (B) FANCD2 did not have a significant effect on irradiation-, MMC- or UV-induced NF-kB activation. FA-D2 and FA-
D2/D2 fibroblast cells were transfected with pNFkB-Luc (100 ng) and pRL-CMV (10 ng). Cells were treated with irradiation (1. 5 Gy), MMC (10, 20 ng/
ml) or UV (100, 400 J/m
2). Fold activation represents the mean (6 s.d) luciferase values of indicated cells normalized with respect to un-stimulated FA-
D2/vec cells, from three independent experiments.
doi:10.1371/journal.pone.0023324.g001
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sequences from the coding regions of the TNF-a gene. Stronger
binding to FANCD2 was observed with the kB1oligonucleotide
than with the kB2 or k3 oligonucleotide, while FANCD2 could not
bind to the oligonucleotide from coding regions (Fig. 6B. Moreover,
a mutation in the kB1 oligonucleotide (Fig. 6A significantly reduced
its FANCD2 binding (Fig. 6B. In addition, we also performed
EMSA, using labeled kB1 oligonucleotide and 2 mg of nuclear
extracts from HEK293 cells transfected with empty vector,
Flag-tagged FANCD2WT, FANCD2KR, or FANCD2KR-Ub.
FANCD2WT, FANCD2KR and FANCD2KR-Ub display similar
kB1 oligonucleotide binding activity. These results showed that
FANCD2 binds to kB1 oligonucleotide sequence specifically.
However, monoubiquitination is not required for FANCD2 binding
to the kB1site oligonucleotide. FANCD2 was reported to bind to
double stranded DNA ends and Holliday junctions[35]; moreover,
sequence specific binding of FANCD2 at telomeric sequences has
been reported [36]. Thus, these data demonstrated that FANCD2
binds to some specific DNA sequences.
To investigate whether FANCD2 was recruited to the NF-kB-
like site in the TNF-a promoter, we employed a chromatin
immunoprecipitation (ChIP) assay. HeLa cells were transfected
with Flag-tagged wild-type FANCD2 or Flag-tagged monoubiqui-
tination site mutant FANCD2 (FANCD2KR), the ChIP assays
were performed using anti-Flag antibodies. PCR primers were
designed to amplify a proximal or a distal region of the TNF-a
promoter, containing the kB1or k3 site, respectively, or to amplify
a coding region in TNF-a. FANCD2WT bound to the distal
region containing the kB1site with higher affinity than did
FANCD2KR, and neither FANCD2WT nor FANCD2KR bound
the proximal promoter region or the coding regions (Fig. 6C).
Post-translational modifications of histones regulate chromatin
structure and the dynamics of transcription. Acetylation of histone
H4 is a prevalent and reversible modification that is used as a
marker of transcriptional activation[37]. We performed ChIP
assays using antibodies recognizing acetylated histone H4. We
found that the kB1andk3sites of the TNF-a promoter in
FANCD2-deficient cells contained acetylated histone H4 at 2 h
or 24 h after TNF-astimulation, whereas in FANCD2-proficient
cells the histone H4 at these sites were not detectably acetylated
(Fig. 6D). These data suggested that FANCD2 deficiency
significantly enhanced TNF-a promoter activity, and resulted in
TNF-a overproduction.
Discussion
FA proteins functions in repair or bypass of interstrand cross-
links (ICLs) during replication, and the hallmark of FA-deficient
cells is hypersensitivity to ICLs that accompany chromosome
aberrations[1,8]. FA-deficient cells also overproduce TNF-
a[15,16]. Moreover, in FANCC-deficient murine hematopoietic
stem cells, overproduction of and hypersensitivity to TNF-a
results in bone marrow hypoplasia and long-term exposure of
these cells to TNF-a induced clonal evolution that led to
myelogenous leukemia[13,17]. However, how disruption of the
other FA proteins, such as FANCD2, up-regulate production of
TNF-a and results in chronic inflammation has not been
addressed.
In this work, we showed that FANCD2 directly bound to the
distal region of the TNF-a promoter which contains an NF-kB
consensus sequence (kB1 site), leading to repression of its
transcriptional activity. In addition, we demonstrated that
FANCD2 negatively regulated NF-kB transcriptional activity in
a monoubiquitination-dependent manner (Fig. 4A), and the
monoubiquitiantation site mutant of FANCD2 could not be
recruited to the kB1 site of TNF-a promoter region (Fig. 6C).
However, monoubiquitination itself is not required for FANCD2
binding to the kB1 site oligonucleotide (Fig. 6B, S3). We
previously showed that monoubiquitination of FANCD2 is
required for targeting of FANCD2 to chromatin [28]. These
results suggest that monoubiquitination is essential for FANCD2 to
translocate to chromatin for binding to the TNF-apromoter region
in transcriptional activity. Although the precise mechanism is still
unclear, FANCD2 deficiency enhanced histone acetylation of
TNF-apromoter region and increased TNF-a mRNA (Fig. 4B,
6D), resulted in overproduction of TNF-a observed in FA patients.
Histone acetylation is a positive mark associated with transcrip-
tionally active chromatin, whereas deacetylated histones are found
in closed, inactive chromatin[38]. These data suggested that
FANCD2 induces TNF-a gene specific regulation at the level of
Figure 2. FANCD2-deficient fibroblast cells showed increased
sensitivity to TNF-a. (A) FA-D2/vec and FA-D2/D2 fibroblast cells
were stimulated for indicated time at 37uC with TNF-a(100 ng/ml), and
cell lysates were examined by immunoblotting (IB) using anti-phospho
(P) Ser 32/36 IkBa or anti-a-tubulin. FA-D2 fibroblast cells showed a
higher NF-kB response to TNF-a than did FA-D2/D2 cells. (B) FA-D2/vec
and FA-D2/D2 fibroblast cells were cultured for indicated times with
TNF-a5ng/ml). Exposure to TNF-ainduced significantly decreased the
amount of proteins in FA-D2/vec cells. The amount of IkB-a protein was
represented as the ratio of IkB-a protein to a-tubulin and normalized
with respect to unstimulated FA-D2/vec cells.
doi:10.1371/journal.pone.0023324.g002
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23324Figure 3. Enhanced TNF-a-induced p65/RelA nuclear translocation in FANCD2-deficient fibroblast cells. (A) FANCD2 deficiency
enhanced TNF-a-induced nuclear localization of p65. FA-D2/vec and FA-D2/D2 fibroblast cells were cultured for indicated times with TNF-a5ng/ml).
Cytoplasmic and nuclear extracts were prepared as described in ‘‘Materials and Methods’’ for immunoblot analysis. The amount of nuclear p65
protein was represented as the ratio of nuclear p65 protein to LaminBand normalized with respect to unstimulated FA-D2/vec cells. (B) Nuclear
translocation of p65 was increased in FA-D2/vec cells. FA-D2/vec and FA-D2/D2 fibroblast cells were cultured for 24 h with or without TNF-a5ng/ml)
and immunostained with anti-p65 antibody (green). Nuclei were stained with Hoechst (blue in Merge).
doi:10.1371/journal.pone.0023324.g003
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modifications.
These data unravel the molecular links connecting disruption of
the FANCD2 with increased inflammation due to TNF-aover-
production. Our results clearly indicated that FANCD2 directly
represses an immune response by regulating the transcriptional
activity of an inflammatory mediator, TNF-a. These observations
established a new function for the FANCD2 in addition to its well-
documented role in preventing genome instability as a genome
caretaker. The disruption of these two functions might have a
significant impact on morbidity in FA patients. Thus, our study
indicates a mechanism that links the FA protein FANCD2 with the
inflammation response.
Materials and Methods
Reagents
Recombinant human TNF-a (210-TA) was purchased from
R&D systems. MMC was purchased from Kyowa Hakkou (Tokyo,
Japan). Antibody to IkBa (4814) and Phospho-IkBa (9246) were
purchased from Cell Signaling. Antibody to H4-Ac (06-866) was
purchased from Millipore. Antibodies to p65/RelA (sc-109) and
Lamin B (sc-6217) were purchased from Santa Cruz Biotechnol-
ogies. Antibodies to FLAG (F3165) and a-Tubulin (T9026) were
purchased from SIGMA.
Plasmids and siRNA
pNFkB-Luc was purchased from Clontech (Mountain View,
CA). pTNF-awt-luc was generated by Human TNF-a promoter
sequence[34] (21173 to 1130 nt) PCR amplified with primers (59-
cggggtaccGAGGGACAGAGGGCTCAAAGG-39,5 9-cggaagcttG-
GAAGAGAACCTGCCTGGCAG-39) from 293 cells, digested
Figure 4. FANCD2 negatively regulates NF-kB activity and TNF-
a transcription. (A) Overexpression of FANCD2 WT or FANCD2KR-Ub
(FANCD2 K561R-Ub fusion), but not the K561R mutant (FANCD2KR),
inhibited NF-kB-dependent transcriptional activity. HEK293 cells were
transfected with FANCD2 WT, FANCI, FANCG, FANCC, FANCD2 KR, or
FANCD2 KR-Ub (each 100 ng) and pNFkB-Luc (100 ng) and pRL-CMV
(10 ng). Cells were treated with or without TNF-a(20 ng/ml) for 8 h.
Cells were harvested, and dual luciferase assays were performed. Fold
activation represents the mean (6 s.d) luciferase values of TNF-
astimulated cells normalized with respect to unstimulated cells, from
three independent experiments. (B) FA-D2/vec and FA-D2/D2 fibroblast
cells were treated with TNF-a (5 ng/ml) for the indicated periods, and
real-time PCR analysis of TNF-a mRNA expression in these cells was
performed. Gene expression results represent four independent
experiments, normalized with respect to unstimulated FA-D2/vec cells,
mean (6 s.d) from triplicate values are shown.
doi:10.1371/journal.pone.0023324.g004
Figure 5. Disruption of FACD2 enhances promoter activity of
TNF-a gene. (A) Real-time PCR analysis of TNF-a mRNA expression in
FA-D2 (PD20) cells, after transfection with FANCD2 WT, FANCD2 K561R,
or empty vector. Cells were treated with or without TNF-a(20 ng/ml).
Overexpression of FANCD2 WT, but not FANCD2 K561R, could inhibit
TNF-a mRNA expression. Results represent three independent exper-
iments, normalized with respect to those obtained from cells expressing
empty vector, shown are the mean (6 s.d) from triplicate experiments.
(B) Schematic representation of the TNF-a promoter/reporter gene
construct. FA-D2 cells (FA-D2, FA-D2/vec cells) showed higher TNF-a-
induced TNF-a transcriptional activity than FANCD2-expressing cells
(FA-D2/D2). Fold activation represents the mean (6 s.d) luciferase
values of TNF-a-stimulated cells normalized with respect to FA-D2 cells
from three independent experiments.
doi:10.1371/journal.pone.0023324.g005
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e23324Figure 6. FANCD2 directly binds to the TNF-a promoter. (A) Schematic representation of the promoter region of the TNF-a gene and three NF-
kB consensus sites (kB1, kB2, k3)[34] used in gel-shift assays; site-directed mutations at kB1 are shown. (B) EMSA assay demonstrated that FANCD2
bound strongly and specifically to an NF-kB binding site previously described in the TNF-a genomic sequence. Site-directed mutation at kB1 affected
FANCD2 binding based on the EMSA assay. (C) FANCD2 associated with the promoter region of TNF-a but not with the coding region. Lysates of
HeLa cells expressing FLAG-FANCD2WT or FLAG-FANCD2K561R were subjected to ChIP with indicated antibodies (FLAG antibody) followed by PCR
amplification of the TNF-a promoter (kB1 or kB3) or coding DNA sequence as indicated in manual (EZ CHIP, upstate). Immunoprecipitated DNA and
input DNA were analyzed by qPCR amplification of TNF-a promoter (kB1) and GAPDH sequences, and represented as % input (kB1) / % input
(GAPDH). Results represent three independent experiments, the mean (6 s.d) from triplicated values are shown. (D) FA-D2 and FA-D2+D2 cells were
stimulated with TNF-a for the indicated periods and analyzed by ChIP (AcH4). Immunoprecipitated DNA and input DNA were analyzed by qPCR
amplification of NF-kB promoter (kB1 or kB3) sequences as indicated. ChIP data are presented as %input (gene specific)/%input (GAPDH) and were
normalized with respect to those obtained in unstimulated FA-D2/vec cells. Results represent three independent experiments; means (6 s.d) from
triplicate values are shown.
doi:10.1371/journal.pone.0023324.g006
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akB1-mt-luc was generated by site-directed mutagenesis at site kB1
with primers (59-GAGTATGGGGACCCCCCCTTAA-39,5 9-
TTAAGGGGGGGTCCCCATACTC-39) using pTNF-awt-luc
as a template. All constructs were verified by DNA sequencing.
ControlsiRNAandhumanp65siRNAonTARGETSMARTpool
were purchased from Dharmacon. Transfect reagents used was
DharmaFECT (Dharmacon).
Cell culture conditions and luciferase assays
SV-40 transformed FA-D2 fibroblasts PD20 (FA-D2), PD20
expressing empty vector (FA-D2/vec), PD20 complemented with
human FANCD2 (FA-D2/D2), FA-C fibroblasts PD331 (FA-C),
PD331 complemented with human FANCC (FA-C/C) were gifts
from Dr. Fang Zhang (Fanconi Anemia Cell Repository, The
Oregon Health and Science University). GM6914 FANCA-null
fibroblasts (FA-A) and GM6914 complemented with human
FANCA (FA-A/A) were gifts from Dr. Takayuki Yamashita
(Gunma University). These cells were cultured at 37uC with 5%
CO2 using a-minimal essential medium supplemented with 20%
fetal calf serum. HeLa cells and HEK293 cells were from ATCC.
These cells were grown in DMEM medium supplemented with
10% fetal calf serum at 37uC with 5% CO2. For luciferase assays,
cells (85–90 % confluency in 96-well plates) were transiently
transfected with 100 ng of indicated luciferase reporter plasmid
(pNF-kB-Luc, pTNF-awtLuc and pTNF-a mtLuc and 10 ng of
phRL-TK (Promega, Madison, WI, USA) using LipofectAMINE
2000 regent (Invitrogen), following the manufacturer’s protocol.
Cells were harvested 24 h after transfection and incubated with or
without indicated reagents (TNF-aMMC) for 8–24 h, and cell
lysates were assayed for luciferase activity using the dual luciferase
assay system (Promega, Madison, WI, USA). Firefly luciferase
activity was corrected for transfection efficiency using the Renilla
luciferase activity. Results presented are the average of triplicate
experiments with the S.D. values shown as error bars. P-value was
calculated from three independent experiments using a t-test.
Subcellular fractionation and detection of cytoplasmic or
nuclear NF-kB
For fractionation experiments, cells incubated with TNF-
a5 ng/ml) for indicated time were collected by centrifugation
and washed in PBS. The cell pellet containing 5610
6 cells were
suspended in 100 mL hypotonic buffer (50 mM Tris [pH 7.4],
10 mM NaCl, 5 mM EDTA, 0.05% Nonidet P-40 [NP-40])
containing protease inhibitor, 1 mM NaF, and 1 mM Na3VO4.
After 10 minutes on ice, the lysate was centrifuged for 10 min at
500 g at 4uC, and the supernatant was collected as cytoplasmic
lysates. The pellet was washed 5 times in hypotonic buffer
containing 0.1% NP-40, and the remaining pellet was suspended
in 100 mL RIPA buffer (20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1 mM Na2EDTA, 1 mM EGT, 1% NP-40, 1% sodium
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin) containing
protease and phosphatase inhibitor. After 10 minutes, the lysate
was centrifuged at 20,000 g for 15 minutes, and the supernatants
was collected as nuclear lysates[39].
Western blotting analysis
Whole-cell lysates (prepared with SDS sample buffer), cytoplas-
mic or nuclear fractions were separated with polyacrylamide gel,
transferred to a polyvinylidene difluoride membranes (Millipore),
and detected with anti human IkBa, Phospho-IkBa, p65/RelA,
Lamin B or a-Tubulin antibodies and ECL reagents (GE
Healthcare, Piscataway, New Jersey).
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 10 minutes,
followed by 6 min permeabilization in Triton buffer (0.5% Triton
X-100 in PBS) at room temperature. Coverslips were blocked with
5% BSA in PBS and then incubated with primary antibody to
RelA/p65 for 1 hour. Cells were washed and incubated with
secondary antibody conjugated to Alexa Fluor 488 (Molecular
Probes). DNA was stained with Hoechst (Sigma). Fluorescence
microscopy was performed on a FV1000 microscope (Olympus).
Images were then imported in Adobe Photoshop Element 6
(Adobe Systems, San Jose, CA), where adjustments were made for
the whole images for brightness and contrast.
Reverse transcription and quantitative PCR (RT–qPCR)
Total RNA from FA-D2 fibroblast cells (FA-D2/vec), its
corrected cells (FA-D2/D2) and FA-D2 fibroblast cells tranfected
with pFlag-FANCD2WT or pFlag- FANCD2KR was isolated
with RNeasy (Qiagen). Total RNA was reverse transcribed with an
oligo (dT) primer using PrimeScript RT reagent Kit (Takara).
Complementary DNA was analyzed in triplicate by qPCR
amplification using SYBR Premix Ex Taq II (Takara) with
primers to the TNF-a (59-CATGATCCGGGACGTGGAGC-39,
59-CTGATTAGAGAGAGGTCCCTG-39) or GAPDH (59-C-
TCTGCTCCTCCTGTTCGAC-39,5 9-ACGACCAAATCCG-
TTGACTCC-39)}. The PCR amplification conditions were:
95uC (3 s), 42 cycles of 94uC (5 s), 60uC (30 s). Data are presented
as fold induction over GAPDH gene and normalized with respect
to those obtained in unstimulated FA-D2/vec cells (Figure 3B), or
in pFLAG expressing cells (Figure 3D).
Chromatin immunoprecipitaion (CHIP) assays
FA-D2+Vec cells, FA-D2+D2 cells or HeLa cells transfected
with 24 mg of the indicated plasmids (Flag-FANCD2WT,
FANCD2KR) using LipofectAMINE 2000 regent (Invitrogen),
grown overnight in 100-mm dishes to 60–70% confluency cells.
Plates were returned to the incubator for 24 h. At this time, cells
were cross-linked with formaldehyde, harvested, and chromatin
immunoprecipitations were performed using EZ-ChiIP (Milli-
pore), following the manufacturer’s protocol. Each ChIP sample
was also subjected to PCR with primers to the distal promoter of
TNF-a includingkB1 site (59-CCACAGCAATGGGTAGGA-
GAATG-39,5 9-TTCATGAAGCTCTCACTTCTCAG-39), the
proximal promoter includingk3 site (59-GGAGAAGAAACCG-
AGACAGA-39,5 9-CTCTGCTGTCCTTGCTGAGGGAG-39)
and the coding region (59-TCCAGACTTCCTTGAGACAC-39,
59-TTGTTCAGCTCCGTTTTCACGG-39). Antibodies used in
the ChIP procedure include antibody to H4-Ac, FLAG as well as
rabbit anti-mouse IgG and mouse anti-rabbit IgG. Immunopre-
cipitated DNA and input DNA were amplified with gene-specific
and GAPDH primers (59-TACTAGCGGTTTTACGGGCG-39,
59-TCGAACAGGAGGAGGAGAGAGCGA-39) by qPCR, using
input DNA to generate a standard curve. ChIP data is represented
as %input (gene specific)/%input (GAPDH) (Figure 4D), and
represented as %input (Figure 4C).
Purification of human FANCD2
The His6-tagged human FANCD2 (hFANCD2) protein was
overexpressed in Sf9 insect cells, using the Bac-to-Bac Baculovirus
Expression System (Invitrogen). Sf9 cells were infected with
recombinant viral particles containing the hFANCD2 gene, and
were cultured for 72 h. The cells were then harvested, and were
resuspended in 20 mL TGM-0.5 buffer (20 mM Tris-HCl
[pH 8.0], 10% glycerol, 2 mM 2-mercaptoethanol, and 0.5 M
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cells were disrupted by sonication on ice. The supernatant was
separated from the debris by centrifugation (27,200 x g)a t4 uC for
20 min, and was then mixed gently with Ni-NTA agarose beads
(6 mL; Qiagen) at 4uC for 1 h. The Ni-NTA beads were washed
with 180 mL TGM-0.5 buffer containing 5 mM imidazole, and
His6-tagged hFANCD2 was eluted with a 100 mL linear gradient
of 5 to 400 mM imidazole in TGM-0.5 buffer. The His6-tag was
removed from hFANCD2 by digestion with thrombin protease
(GE Healthcare; 2 U/mg protein) during dialysis against 5 L of
TGM-0.2 buffer (20 mM Tris-HCl [pH 8.0], 10% glycerol, 2 mM
2-mercaptoethanol, and 0.2 M NaCl). The protein sample
containing hFANCD2 without the His6-tag was then loaded onto
a Heparin Sepharose CL-6B column (4 mL; GE Healthcare)
equilibrated with TGM-0.2 buffer. The column was washed with
80 mL TGM-0.2 buffer, and hFANCD2 was eluted with an
80 mL linear gradient of 0.2 to 1 M NaCl in TGM-0.2 buffer.
The fractions containing hFANCD2 were immediately dialyzed
against TGM-0.2 buffer (5L). After dialysis, the sample was then
loaded onto a Q Sepharose Fast Flow column (4 mL; GE
Healthcare) equilibrated with TGM-0.2 buffer. The column was
washed with 80 mL TGM-0.2 buffer, and hFANCD2 was eluted
with a 40 mL linear gradient of 0.2 to 1 M NaCl in TGM-0.2
buffer. The fractions containing hFANCD2 were immediately
dialyzed against TGM-0.2 buffer (5 L). hFANCD2 was loaded on
a Mono Q column (1 mL; GE Healthcare) equilibrated with
TGM-0.2 buffer. The column was washed with TGM-0.2 buffer
(10 mL), and hFANCD2 was eluted with a linear gradient of 0.2 to
1 M NaCl in TGM-0.2 buffer. Purified hFANCD2 was dialyzed
against 2 L of TGM-0.2 buffer. The protein concentration was
determined by the Bradford method, using bovine serum albumin
as the standard protein.
Nuclear Extracts and Electrophoretic mobility shift assay
HEK293 cells were transiently transfected with 24 mg of the
indicated plasmids (empty vector, Flag tagged-FANCD2WT,
FANCD2KR, FANCD2KR-Ub) using LipofectAMINE 2000
regent (Invitrogen), following the manufacturer’s protocol. Cells
were harvested 24 h after transfection and nuclear extracts were
prepared as described previously [40]. Samples (200 ng) of
recombinant FANCD2 or nuclear extracts (2 mg) were incubated
with 32P-labeled NF-kB1 consensus sequence (kB1:59-GAG-
TATGGGGACCCCCCCTTAA-39, kB2:59-GGGTCTGTGAA-
TTCCCGGGGGT-39, k3: 59-GCTCATGGGTTTCTCCAC-
CAAG-39)o rkB1mutant sequence (kB1 mut:59-GAGGATCCG-
GACCCCCCCTTAA-39) oligonucleotides for 20 min at room
temperature in binding buffer [20 mM HEPES at pH 7.6, 5 mM
EDTA, 1 mM DTT, 150 mM KCl, 50 mM (NH4)2SO4, and 1%
Tween-20 (v/v)]. Following electrophoresis on native 4%
polyacrylamide gels, FANCD2-NF-kB1 complexes were visualized
by autoradiography.
Supporting Information
Figure S1 FANCD2 mutant dose not repress TNF-
a-induced NF-kB activity. A. Transiently expressed
FANCD2WT repressed enhanced NF-kB activity in FANCD2
deficient cells (PD20:FA-D2). In contrast, FANCD2 monoubiqui-
tination-defective mutant (K561R: D2KR) and FANCC did not
change the NF-kB activity. B. FANCA deficiency did not
significantly enhanced NF-kB activity (p=0.21114).
(EPS)
Figure S2 Knockdown of endogeneous p65 represses
NF-kB activity. Cells transfected with the indicated siRNA were
treated with TNF-a(20 ng/ml) and NF-kB-luciferase reporter
expression was assayed 8 h later.
(EPS)
Figure S3 EMSA analysis of nuclear extracts isolated
from HEK293 cells expressing FANCD2 WT or FANCD2
mutant. EMSA was conducted using labeled kB1 fragments and
2 mg of nuclear extracts from HEK293 cells transfected with
empty vector, Flag-tagged FANCD2 WT, FANCD2 KR, or
FANCD2 KR-Ub.
(EPS)
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